{"id":75321,"date":"2026-08-19T12:35:08","date_gmt":"2026-08-19T04:35:08","guid":{"rendered":"https:\/\/flcube.com\/?p=75321"},"modified":"2026-08-19T12:35:09","modified_gmt":"2026-08-19T04:35:09","slug":"genrix-bios-gr2302-bispecific-antibody-receives-nmpa-ind-approval-for-chronic-hepatitis-b-tcr-mimic-t-cell-engager-targets-hbv-infected-hepatocytes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75321","title":{"rendered":"Genrix Bio&#8217;s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B \u2013 TCR\u2011Mimic T\u2011Cell Engager Targets HBV\u2011Infected Hepatocytes"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Chongqing Genrix Bio Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/688443:SHA\">SHA: 688443<\/a>) announced that its investigational product <strong>GR2302 (subcutaneous injection formulation)<\/strong> has received <strong>Investigational New Drug (IND) approval<\/strong> in China for clinical trials targeting <strong>chronic hepatitis B (CHB)<\/strong>, advancing a first\u2011in\u2011class immunotherapy approach against one of Asia&#8217;s most prevalent viral diseases.<\/p>\n\n\n\n<h2 id=\"h-ind-approval-summary\" class=\"wp-block-heading\">IND Approval Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Genrix Bio (SHA: 688443)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>GR2302 (subcutaneous injection formulation)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Bispecific antibody (TCR\u2011mimic \u00d7 anti\u2011CD3)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Chronic hepatitis B (CHB)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>IND approved in China for clinical trials<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>19 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-gr2302\" class=\"wp-block-heading\">Drug Profile \u2013 GR2302<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform:<\/strong> In\u2011house developed <strong>bispecific antibody<\/strong> combining a <strong>TCR\u2011mimic (TCRm)<\/strong> antibody with an <strong>anti\u2011CD3<\/strong> antibody<\/li>\n\n\n\n<li><strong>Mechanism \u2013 TCRm Arm:<\/strong> Functionally similar to a <strong>T\u2011cell receptor (TCR)<\/strong>, the TCRm recognizes <strong>peptide\u2011MHC complexes<\/strong> assembled from specific intracellular antigen peptides and MHC molecules presented on the cell surface; the TCRm component in GR2302 specifically binds with <strong>high affinity to the peptide\u2011MHC complex of the HBV S protein<\/strong><\/li>\n\n\n\n<li><strong>Mechanism \u2013 T\u2011Cell Engagement:<\/strong> GR2302 <strong>recruits T cells to kill HBV\u2011infected hepatocytes<\/strong> of the <strong>HLA\u2011A02 subtype<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Potential:<\/strong> Holds potential for treating <strong>HBV\u2011induced hepatitis B and liver cancer<\/strong>, extending the asset&#8217;s relevance beyond CHB into hepatocellular carcinoma<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Large Unmet Need:<\/strong> China carries one of the world&#8217;s highest burdens of chronic hepatitis B, with tens of millions of patients and limited options capable of achieving functional cure \u2014 making novel mechanisms like TCRm\u2011based T\u2011cell engagers strategically valuable.<\/li>\n\n\n\n<li><strong>Differentiated Modality:<\/strong> By targeting an <strong>intracellular HBV antigen presented as a peptide\u2011MHC complex<\/strong>, GR2302 can reach HBV\u2011infected cells that conventional antibodies cannot, a potential advantage over surface\u2011antigen\u2011directed approaches.<\/li>\n\n\n\n<li><strong>Oncology Bridge:<\/strong> The stated potential in <strong>HBV\u2011induced liver cancer<\/strong> positions GR2302 within both infectious disease and oncology franchises, broadening the commercial pathway for <strong>Genrix Bio<\/strong>.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> First\u2011in\u2011human dose\u2011escalation design and safety readouts, HLA\u2011A02\u2011restricted patient selection strategy, and potential expansion studies in hepatocellular carcinoma.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development, regulatory outcomes, and commercial expectations for GR2302. Actual results may differ due to risks including early\u2011stage clinical uncertainty, regulatory decisions, and competitive dynamics in chronic hepatitis B therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688443_20260819_A1ER.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688443_20260819_A1ER.\"><\/object><a id=\"wp-block-file--media-eef83352-793f-4e51-ae80-688805c3d0f9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688443_20260819_A1ER.pdf\">688443_20260819_A1ER<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688443_20260819_A1ER.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-eef83352-793f-4e51-ae80-688805c3d0f9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) announced that its investigational product GR2302 (subcutaneous&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,3000,877,89],"class_list":["post-75321","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-genrix-biopharmaceutical","tag-sha-688443","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Genrix Bio&#039;s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B \u2013 TCR\u2011Mimic T\u2011Cell Engager Targets HBV\u2011Infected Hepatocytes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) announced that its investigational product GR2302 (subcutaneous injection formulation) has received Investigational New Drug (IND) approval in China for clinical trials targeting chronic hepatitis B (CHB), advancing a first\u2011in\u2011class immunotherapy approach against one of Asia&#039;s most prevalent viral diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75321\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genrix Bio&#039;s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B \u2013 TCR\u2011Mimic T\u2011Cell Engager Targets HBV\u2011Infected Hepatocytes\" \/>\n<meta property=\"og:description\" content=\"Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) announced that its investigational product GR2302 (subcutaneous injection formulation) has received Investigational New Drug (IND) approval in China for clinical trials targeting chronic hepatitis B (CHB), advancing a first\u2011in\u2011class immunotherapy approach against one of Asia&#039;s most prevalent viral diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75321\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-19T04:35:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-19T04:35:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75321#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75321\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Genrix Bio&#8217;s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B \u2013 TCR\u2011Mimic T\u2011Cell Engager Targets HBV\u2011Infected Hepatocytes\",\"datePublished\":\"2026-08-19T04:35:08+00:00\",\"dateModified\":\"2026-08-19T04:35:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75321\"},\"wordCount\":397,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Genrix Biopharmaceutical\",\"SHA: 688443\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75321#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75321\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75321\",\"name\":\"Genrix Bio's GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B \u2013 TCR\u2011Mimic T\u2011Cell Engager Targets HBV\u2011Infected Hepatocytes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-19T04:35:08+00:00\",\"dateModified\":\"2026-08-19T04:35:09+00:00\",\"description\":\"Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) announced that its investigational product GR2302 (subcutaneous injection formulation) has received Investigational New Drug (IND) approval in China for clinical trials targeting chronic hepatitis B (CHB), advancing a first\u2011in\u2011class immunotherapy approach against one of Asia's most prevalent viral diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75321#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75321\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75321#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genrix Bio&#8217;s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B \u2013 TCR\u2011Mimic T\u2011Cell Engager Targets HBV\u2011Infected Hepatocytes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genrix Bio's GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B \u2013 TCR\u2011Mimic T\u2011Cell Engager Targets HBV\u2011Infected Hepatocytes - Insight, China&#039;s Pharmaceutical Industry","description":"Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) announced that its investigational product GR2302 (subcutaneous injection formulation) has received Investigational New Drug (IND) approval in China for clinical trials targeting chronic hepatitis B (CHB), advancing a first\u2011in\u2011class immunotherapy approach against one of Asia's most prevalent viral diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75321","og_locale":"en_US","og_type":"article","og_title":"Genrix Bio's GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B \u2013 TCR\u2011Mimic T\u2011Cell Engager Targets HBV\u2011Infected Hepatocytes","og_description":"Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) announced that its investigational product GR2302 (subcutaneous injection formulation) has received Investigational New Drug (IND) approval in China for clinical trials targeting chronic hepatitis B (CHB), advancing a first\u2011in\u2011class immunotherapy approach against one of Asia's most prevalent viral diseases.","og_url":"https:\/\/flcube.com\/?p=75321","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-19T04:35:08+00:00","article_modified_time":"2026-08-19T04:35:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75321#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75321"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Genrix Bio&#8217;s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B \u2013 TCR\u2011Mimic T\u2011Cell Engager Targets HBV\u2011Infected Hepatocytes","datePublished":"2026-08-19T04:35:08+00:00","dateModified":"2026-08-19T04:35:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75321"},"wordCount":397,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Genrix Biopharmaceutical","SHA: 688443","Viral hepatitis"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75321#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75321","url":"https:\/\/flcube.com\/?p=75321","name":"Genrix Bio's GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B \u2013 TCR\u2011Mimic T\u2011Cell Engager Targets HBV\u2011Infected Hepatocytes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-19T04:35:08+00:00","dateModified":"2026-08-19T04:35:09+00:00","description":"Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) announced that its investigational product GR2302 (subcutaneous injection formulation) has received Investigational New Drug (IND) approval in China for clinical trials targeting chronic hepatitis B (CHB), advancing a first\u2011in\u2011class immunotherapy approach against one of Asia's most prevalent viral diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75321#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75321"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75321#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Genrix Bio&#8217;s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B \u2013 TCR\u2011Mimic T\u2011Cell Engager Targets HBV\u2011Infected Hepatocytes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75321"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75321\/revisions"}],"predecessor-version":[{"id":75323,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75321\/revisions\/75323"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}